for detection of Epstein-Barr virus (EBV) DNA has been proposed as a minimally invasive method for establishing the diagnosis of human immunodeficiency virus-related primary central nervous system lymphoma (PCNSL). In a review of the operational characteristics of this test in our clinical practice, the positive predictive value of CSF PCR for EBV for establishing the diagnosis of PCNSL was only 29%. Of 7 patients with CSF PCR positive for EBV, 2 had PCNSL, and 5 received alternative diagnoses (specificity, 79.1%).
a procedure-associated mortality of up to 3.1%, and may be nondiagnostic in up to 50% of cases [1] .
Epstein-Barr virus (EBV) has been consistently associated with PCNSL in patients with AIDS [2] . The presence of EBV DNA in the CSF of patients with HIV infection is thus a potentially sensitive and specific marker for the diagnosis of PCNSL [3] . EBV DNA has also been described in the CSF of HIV-infected patients without brain lesions who later developed PCNSL and has been proposed as a potential predictor of the future development of PCNSL [4, 5] .
At our institution, PCR of CSF for detection of EBV DNA has become a frequently ordered test in the evaluation of HIVinfected patients with CNS disease. Our goal in this study was to review the clinical significance of detection of EBV DNA in the CSF for this patient population, with a focus on correlating PCR results with the patients' final diagnosis.
Patients and methods. CSF specimens were those obtained from HIV-infected patients and sent to the clinical laboratory at Brigham and Women's Hospital (BWH; Boston) between January 1998 and November 2002 for detection of EBV by PCR. We reviewed the results retrospectively. All patients had clinical CNS disease and had undergone lumbar puncture at the discretion of the primary medical team or at the recommendation of an infectious diseases consultant. Results of PCR for EBV were reviewed, and clinical, microbiologic, and pathologic data were recorded for each patient. Final diagnoses were established on the basis of analysis of tissue biopsy specimens or clinical data, if no biopsy was performed. Tissue biopsy specimens were sent to Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories for processing and were analyzed by PCR, with primers directed at the BamH1W fragment of the EBV genome.
Results. CSF specimens obtained from 26 patients with HIV infection and CNS disease were sent to BWH for detection of EBV by PCR between January 1998 and November 2002 (table 1). The median CD4 cell count was 51 cells/mm 3 (range, 2-891 cells/mm 3 ) , and the median HIV RNA load for the 24 patients with detectable virus was 303,000 copies/mL (range, 272 to 1750,000 copies/mL). The presence of lymphocytic pleocytosis (defined as 15 WBCs per mm 3 of CSF, with lymphocytic predominance) was marginally associated with detection of EBV by PCR ( , by Fisher's exact test). P p .047 Seven of the 26 patients had CSF specimens positive for EBV DNA. Of these, 2 received a diagnosis of PCNSL, and 5 received an alternative diagnosis (2 had HIV encephalopathy, 2 had toxoplasmic encephalitis, and 1 had a cryptococcoma). At the time of writing, these 5 patients had been observed for a median of 37 months (range, 11-62 months), and none had developed PCNSL. PCR did not detect EBV in 19 patients, and none had PCNSL during a median follow-up period of 10 months. The diagnoses for all patients are listed in table 1.
In this series, PCR of CSF for detection of EBV had a specificity of 79.1% (95% CI, 57.9-92.9) for the diagnosis of PCNSL. The positive predictive value was only 29%. A subgroup of 8 patients had enhancing mass lesions and ultimately negative results of serological testing for Toxoplasma species. In this small subgroup, in which the likelihood of PCNSL might be considered to be high, PCR of CSF obtained from 6 patients was positive for EBV, but only 2 had PCNSL (specificity, 33.3%; 95% CI, 4.3-78). Although both patients with PCNSL had EBV detection by PCR, wide 95% CIs preclude valid comment on sensitivity (sensitivity, 100%; 95% CI, 15.8-100).
Discussion. PCNSL and toxoplasmic encephalitis are leading causes of focal brain lesions in patients with HIV infection. Usual care for HIV-infected patients with enhancing CNS mass lesions and positive serum IgG titers for Toxoplasma species involves empirical treatment for toxoplasmosis, followed by brain biopsy if there is no response to therapy. This empirical approach is necessary because it remains difficult to definitively distinguish between toxoplasmosis and PCNSL with standard anatomic imaging. Magnetic resonance spectroscopy and nuclear imaging studies improve our ability to distinguish these diseases, yet clinical studies show that such studies cannot yet be used to make definitive distinctions [6] [7] [8] [9] [10] . This, coupled with a lack of specific "traditional" CSF findings, has prompted a search for improved diagnostic techniques that shorten the time to diagnosis and reduce the need for biopsy.
Two studies by Cinque et al. [3, 5] investigated the use of PCR to detect EBV in CSF for the diagnosis of virus-associated CNS disease in HIV-infected patients. In the larger of the 2 studies, 500 patients with HIV infection and clinical CNS disease were enrolled. The sensitivity of EBV PCR for the diagnosis of PCNSL was reported to be 97%, and the specificity was reported to be 98%. It should be noted, however, that analysis was performed with the exclusion of patients for whom biopsy or autopsy was not used to prove the final diagnosis. In fact, 62 of the 500 enrolled patients had detectable EBV in CSF; however, clinical diagnoses were reported for only 38. The remaining 24 were excluded from analysis and from specificity calculations. It is possible that these excluded patients actually had favorable clinical outcomes and may not have had PCNSL. This may especially be the case if the lack of biopsy or autopsy information reflected a favorable clinical course. Without the availability of additional clinical information, the true specificity of EBV PCR may have been overestimated.
Other smaller studies have had similar results with regard to the sensitivity and specificity of PCR, with the latter ranging from 89% to 100% [11, 12] . Tachikawa et al. [13] reported a specificity of 78%; however, all 4 patients in this study who had EBV detected in CSF but did not have PCNSL had peripheral lymphoma. Some authors have reviewed the accuracy of combining the use of PCR of CSF for detection of EBV with other studies (e.g., single proton-emission CT and serological testing for Toxoplasma gondii) in an effort to create decisionmaking strategies that help to avoid the need for biopsy, often with favorable results [14] [15] [16] .
In our study, detection of EBV DNA in the CSF was only 79.1% specific for the diagnosis of PCNSL and had a positive predictive value of only 29%. No patient with PCR results positive for EBV and for whom there was no evidence of PCNSL at time of lumbar puncture had developed PCNSL after a median follow-up period of 37 months.
Our study reflects the routine diagnostic use of EBV PCR in a clinical setting at a tertiary care referral hospital in which a diverse group of HIV-infected individuals are treated. The minimal specificity in our study may reflect truly false-positive PCR results, whereby EBV DNA was falsely detected as a result of laboratory contamination during processing. Because specimens were sent to CLIA-certified commercially available laboratories, the tests were not performed under research conditions, as has been the case in other studies. Alternatively, the presence of EBV DNA in CSF may not in fact reflect that PCNSL was a cause of brain lesions in this patient population. By including patients with a wide range of clinical presentations and radiological findings in our analysis, the prevalence of PCNSL was relatively low in our population. However, because patients were included in the study only if their physician had requested the test, the study population reflects clinical practice in our institution. When the subgroup with enhancing mass lesions and negative results of serological tests for Toxoplasma species was analyzed, the specificity remained low.
Improved standardization of the EBV PCR procedure may be required before it can reliably be used in a broad clinical setting. As additional information becomes available with regard to the correlation between quantitative measurement of EBV load and specific diseases, quantitative PCR analysis may prove to be more useful than qualitative PCR analysis in clinical decision making [17, 18] . The use of sensitive methods to amplify EBV DNA could result in false-positive findings, as a result of the presence of EBV-infected B lymphocytes; however, in this small study, there was only a marginal association, and larger studies are needed to determine whether these sensitive methods are independent causes of false-positive test results.
In conclusion, our results suggest that, although detection of EBV DNA in CSF by PCR may be a useful tool to exclude the diagnosis of primary CNS lymphoma, the test has a low positive predictive value when applied to a heterogeneous group of patients with HIV-related neurological disease. Clinicians should not rely on an isolated positive PCR result for detection of EBV in CSF as diagnostic evidence of PCNSL without other supporting clinical and laboratory data.
